Rasagiline transdermal patch

Drug Profile

Rasagiline transdermal patch

Alternative Names: TPU-002RA

Latest Information Update: 14 Apr 2016

Price : $50

At a glance

  • Originator Teikoku Pharma USA
  • Class Antiparkinsonians; Indans; Small molecules
  • Mechanism of Action Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Parkinson's disease

Most Recent Events

  • 14 Apr 2016 Phase-I development is ongoing in USA
  • 02 Dec 2014 Phase-I clinical trials in Parkinson's disease in USA (Transdermal)
  • 02 Dec 2014 Pharmacokinetics data from a phase I trial in Parkinson's disease released by Teikoku Pharma USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top